MedTrace Logo

Efficacy and Safety of Alflorex Bei Reizdarm in Patients With Irritable Bowel Syndrome

NCT04859075 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2022-01-06

No results posted yet for this study

Summary

This Post-Market Clinical-Follow Up (PMCF) study gains data on the efficacy and safety of "Alflorex bei Reizdarm", a probiotic based on Bifidobacterium longum 35624, in the daily use by irritable bowel syndrome (IBS) patients. The aim of this study is the observation of the influence of "Alflorex bei Reizdarm" on typical symptoms, severity score and quality of life of IBS patients in medical practice and everyday use.

Conditions

  • Irritable Bowel Syndrome

Interventions

OTHER

Bifidobacterium longum 35624

1 capsule daily

Sponsors & Collaborators

  • BioTeSys GmbH

    collaborator OTHER

  • Medice Arzneimittel Pütter GmbH & Co KG

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-05
Primary Completion
2021-11-09
Completion
2021-11-09

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04859075 on ClinicalTrials.gov